Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (GB:0HF9)
LSE:0HF9
Holding GB:0HF9?
Track your performance easily
0HF9 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.04 - $14.57
Previous Close$9.84
Volume53.00
Average Volume (3M)3.14K
Market Cap
$2.91B
Enterprise Value$3.10B
Total Cash (Recent Filing)$249.76M
Total Debt (Recent Filing)$444.66M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Feb 26, 2025EPS Estimate
$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding298,805,773
10 Day Avg. Volume1,556
30 Day Avg. Volume3,141
Standard Deviation0.14
R-Squared0.00187
Alpha0.00904
Financial Highlights & Ratios
Price to Book (P/B)16.33
Price to Sales (P/S)5.93
Price to Cash Flow (P/CF)-31.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.28
Enterprise Value/Gross Profit8.57
Enterprise Value/Ebitda-357.12
Forecast
1Y Price Target
$17.33Price Target Upside76.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Amicus News
PremiumCompany Announcements
Amicus Therapeutics Reports Strong Q3 2024 GrowthBulls Say, Bears Say
Bulls Say
Intellectual PropertyThe company settled the Galafold IP litigation with Teva, granting them license to market generic Galafold starting in January 2037, which protects Galafold exclusivity for another 12 years.
Market ExpansionThe company is negotiating reimbursement with multiple EU countries, which could lead to new launches.
Revenue GrowthGalafold revenue has grown significantly, with a notable increase of over $10M sequentially this year, suggesting potential outperformance against consensus expectations.
Bears Say
Litigation RiskConsidering some Galafold patents expire in the late 2020s and the risk of a skinny label approval, the litigation remains a concern.
Patient GrowthIt appears that patient growth quarter over quarter has slowed modestly.
Product LaunchInvestor concerns are noted around the trajectory of the Pompe launch, which may not be as steep as initially expected.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.15% Insiders
31.42% Mutual Funds
38.57% Other Institutional Investors
12.04% Public Companies and
Individual Investors
0HF9 FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest share price was $9.04 and its highest was $14.57 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Currently, no data Available
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 66 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.021.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is $0.02.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 298,805,800 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of -$0.02 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went down -3.647%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Among the largest hedge funds holding Amicus Therapeutics’s share is Perceptive Advisors LLC. It holds Amicus Therapeutics’s shares valued at 300M.
---
Amicus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.33 (76.21% Upside)
$17.33 (76.21% Upside)
Blogger Sentiment
Bullish
GB:0HF9 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $339.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.67%
12-Months-Change
Fundamentals
Return on Equity
-67.09%
Trailing 12-Months
Asset Growth
2.94%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
---
0HF9 Company Deck
---
0HF9 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call displayed a positive sentiment with strong revenue growth, successful product launches, increased guidance, and achievement of non-GAAP profitability. While there are challenges like ongoing litigation and a decrease in cash reserves, they are outweighed by the strong financial and operational performance.Read More>---
0HF9 Stock 12 Month Forecast
Average Price Target
$17.33
▲(76.21% Upside)
Technical Analysis
Amicus
―
ACADIA Pharmaceuticals
―
Allogene Therapeutics
―
Kura Oncology
―
SAGE Therapeutics
―
Best Analysts Covering 0HF9
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+26.62%
reiterated a buy rating 2 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +26.62% per trade.
---